文献速递骨软组织肉瘤与黑色素瘤

帕博利珠单抗对比化疗用于伊匹木单抗难治晚期黑色素瘤的最终分析

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
PubMed 文献 · Eur J Cancer · 2017-01-01

KEYNOTE-002研究最终分析比较帕博利珠单抗2 mg/kg或10 mg/kg每3周与研究者选择化疗用于伊匹木单抗难治晚期黑色素瘤。中位随访28个月时,两剂量组OS较化疗均未达统计学显著改善(2 mg/kg HR 0.86,p=0.117;10 mg/kg HR 0.74,p=0.011,预设界值p<0.01)。PFS、ORR和缓解持续时间在帕博利珠单抗组改善,且不依赖于剂量。

要点

  • 帕博利珠单抗2 mg/kg和10 mg/kg组OS较化疗均未达统计学显著改善。
  • 中位OS:2 mg/kg组13.4个月,10 mg/kg组14.7个月,化疗组11.0个月。
  • 2年生存率:2 mg/kg组36%,10 mg/kg组38%,化疗组30%。

核心结论

  • 帕博利珠单抗2 mg/kg和10 mg/kg组OS较化疗均未达统计学显著改善(预设p<0.01)。
  • PFS、ORR和缓解持续时间在帕博利珠单抗组改善,且不依赖于剂量。

研究设计与样本

  • 随机II期研究KEYNOTE-002(NCT01704287),纳入伊匹木单抗难治晚期黑色素瘤患者。
  • 180例随机至帕博利珠单抗2 mg/kg,181例至10 mg/kg,179例至研究者选择化疗。
  • 化疗进展后允许交叉至帕博利珠单抗。
  • 方案预设最终OS分析在意向治疗人群中进行。

主要发现

  • 中位随访28个月(范围24.1-35.5)时,368例死亡,98例(55%)交叉至帕博利珠单抗。
  • OS:2 mg/kg组HR 0.86(95%CI 0.67-1.10,p=0.117),10 mg/kg组HR 0.74(95%CI 0.57-0.96,p=0.011),均未达统计学显著。
  • 中位OS:2 mg/kg组13.4个月(95%CI 11.0-16.4),10 mg/kg组14.7个月(95%CI 11.3-19.5),化疗组11.0个月(95%CI 8.9-13.8)。
  • 2年生存率:2 mg/kg组36%,10 mg/kg组38%,化疗组30%。
  • III-V级治疗相关不良事件:2 mg/kg组24例(13.5%),10 mg/kg组30例(16.8%),化疗组45例(26.3%)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the protocol-specified final analysis of overall survival (OS) in the KEYNOTE-002 study (NCT01704287) of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory, advanced melanoma. METHODS: In this randomised, phase II study, eligible patients had advanced melanoma with documented progression after two or more ipilimumab doses, previous BRAF or MEK inhibitor or both, if BRAFV600 mutant-positive. Patients were randomised to pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks or investigator-choice chemotherapy. Crossover to pembrolizumab was allowed following progression on chemotherapy. The protocol-specified final OS was performed in the intent-to-treat population. Survival was positive if p < 0.01 in one pembrolizumab arm. RESULTS: A total of 180 patients were randomised to pembrolizumab 2 mg/kg, 181 to pembrolizumab 10 mg/kg and 179 to chemotherapy. At a median follow-up of 28 months (range 24.1-35.5), 368 patients died and 98 (55%) crossed over to pembrolizumab. Pembrolizumab 2 mg/kg (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.67-1.10, p = 0.117) and 10 mg/kg (0.74, 0.57-0.96, p = 0.011) resulted in a non-statistically significant improvement in OS versus chemotherapy; median OS was 13.4 (95% CI 11.0-16.4) and 14.7 (95% CI 11.3-19.5), respectively, versus 11.0 months (95% CI 8.9-13.8), with limited improvement after censoring for crossover. Two-year survival rates were 36% and 38%, versus 30%. Progression-free survival, objective response rate and duration of response improved with pembrolizumab versus chemotherapy, regardless of dose. Grade III-V treatment-related adverse events occurred in 24 (13.5%), 30 (16.8%) and 45 (26.3%) patients, respectively. CONCLUSION: Improvement in OS with pembrolizumab was not statistically significant at either dose versus chemotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017. PMID: 28961465. doi:10.1016/j.ejca.2017.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。